AQST · Aquestive Therapeutics, Inc.
$4.25
+0.00 (+0.00%)
At close · Aug 14
Market Cap
$533.42M
Shares
125.51M
Notices of intent to sell restricted or control shares, filed with the SEC on Form 144 by insiders and affiliates. A Form 144 signals a planned sale — it does not confirm the shares were actually sold.
| Filed | Seller | Relationship | Shares | Approx. Sale | Broker |
|---|---|---|---|---|---|
| 2026-07-15 | Daniel Barber | Officer | 25,000 | 2026-07-15 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-06-23 | JULIE KROP | Director | 25,000 | 2026-06-23 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-06-15 | Daniel Barber | Officer | 25,000 | 2026-06-15 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-05-15 | Daniel Barber | Officer | 8,257 | 2026-05-15 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-11-17 | Carl N. Kraus | Affiliate | 53,100 | 2025-11-17 | J.P. Morgan Securities LLC |
| 2025-10-15 | CASSIE JUNG | Officer | 67,575 | 2025-10-15 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-10-15 | Carl N. Kraus | Officer | 40,544 | 2025-10-15 | J.P. Morgan Securities LLC |
| 2025-10-15 | Peter Boyd | Officer | 10,000 | 2025-10-15 | Merrill |
| 2025-09-29 | Peter Boyd | Officer | 10,000 | 2025-09-26 | Merrill |
| 2025-09-26 | DANIEL BARBER | Director, Officer | 91,343 | 2025-09-26 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-09-19 | DANIEL R BARBER | Officer | 400 | 2025-09-19 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-09-05 | Boyd Peter E. | Officer | 15,000 | 2025-09-05 | Merrill Lynch |
| 2025-09-04 | CASSIE JUNG | Officer | 62,180 | 2025-09-04 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2024-03-15 | Schobel Alexander Mark | Officer | 50,000 | 2024-03-15 | UBS Financial Services Inc. |
| 2024-03-08 | Schobel Alexander Mark | Officer | 25,000 | 2024-03-08 | UBS Financial Services Inc. |
Showing 1–15 of 15 filings
Key facts
CIK
1398733
CUSIP
03843E104
13F (30d)
181 filings
177 filers
Visit website
Investor relations